.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
UBS
Cantor Fitzgerald
McKinsey
McKesson
Queensland Health
Fuji
Johnson and Johnson
AstraZeneca

Generated: November 23, 2017

DrugPatentWatch Database Preview

ISOPAQUE 440 Drug Profile

« Back to Dashboard

Which patents cover Isopaque 440, and when can generic versions of Isopaque 440 launch?

Isopaque 440 is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in ISOPAQUE 440 is calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium. There are two hundred and seventy drug master file entries for this compound. Additional details are available on the calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium profile page.

Summary for ISOPAQUE 440

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
ISOPAQUE 440
calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium
INJECTABLE;INJECTION016847-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ISOPAQUE 440

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
ISOPAQUE 440
calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium
INJECTABLE;INJECTION016847-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Argus Health
QuintilesIMS
Chinese Patent Office
Daiichi Sankyo
Chubb
Moodys
Harvard Business School
Queensland Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot